TL;DR
This study reveals that a significant portion of sporadic ALS/FTD cases share a common molecular signature with C9ORF72-linked ALS/FTD, characterized by aberrant RNA splicing and the aggregation of RNA-binding proteins (RBPs). This suggests a unified RBP proteinopathy mechanism underlying these devastating neurodegenerative diseases, rather than solely focusing on TDP-43.
What Problem Does This Paper Address?
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative diseases that often co-occur, forming a spectrum of clinical and pathological presentations. A hallmark of these diseases is the presence of abnormal protein aggregates, particularly of the RNA-binding protein TDP-43. While the C9ORF72 (C9) gene expansion is a known genetic cause for some ALS/FTD cases, the underlying molecular mechanisms, especially in sporadic (non-C9) forms, remain elusive. Previous work by the authors identified aberrant splicing of RNA targets due to hnRNP H sequestration in C9ALS patients. This paper investigates whether this specific splicing defect and associated protein aggregation are also present in sporadic ALS/FTD, aiming to uncover a common disease mechanism across the ALS/FTD spectrum.
Methods
The researchers employed a multi-pronged approach:
- RNA Extraction and RT-PCR: Total RNA was extracted from postmortem cerebellum samples. They used reverse transcription-polymerase chain reaction (RT-PCR) to analyze the inclusion levels of specific exons in known hnRNP H target transcripts. This allowed them to quantify splicing patterns.
- Biochemical Fractionation (Sarkosyl Extraction): To assess protein aggregation, brain tissue (specifically motor cortex) was fractionated into soluble, sarkosyl-soluble, and sarkosyl-insoluble fractions. Western blotting was then used to detect and quantify the levels of specific RBPs (hnRNP H, TDP-43, FUS, hnRNP A1, etc.) in each fraction. The sarkosyl-insoluble fraction is indicative of aggregated, pathological protein.
- RNA-sequencing (RNA-seq): For a broader view of splicing alterations, RNA-seq was performed on cerebellum samples to analyze transcriptome-wide splicing patterns. This allowed for the identification of differential splicing (DS) events.
- Co-Immunoprecipitation (Co-IP): To investigate physical interactions between aggregated proteins, co-IP experiments were conducted to see if hnRNP H could be pulled down with a TDP-43 antibody from insoluble fractions.
- Statistical Analysis: Various statistical methods, including t-tests, Fisher's exact tests, and correlation analyses (Spearman), were used to compare groups and identify relationships between splicing defects, protein insolubility, and clinical diagnoses.
Datasets
The study utilized postmortem human brain samples from:
- 50 sporadic ALS/FTD patients (including ALS, ALS-FTD, and FTD-MND).
- Control individuals (neurologically normal and SOD1-ALS patients).
- Patients with known C9ORF72 repeat expansions.
RNA-seq data was generated from a subset of these samples. The study did not introduce new benchmark datasets but rather analyzed existing patient cohorts.
Key Insights and Ideas
- "Like-C9" Signature in Sporadic ALS/FTD: A significant finding is that approximately half of sporadic ALS/FTD brains exhibit a splicing signature (dysregulation of hnRNP H targets) and protein aggregation patterns (insoluble hnRNP H and TDP-43) remarkably similar to those seen in C9ORF72-linked ALS/FTD. This challenges the notion that C9 is a unique driver of these specific molecular defects.
- Beyond TDP-43 Centricity: The study casts doubt on a purely TDP-43-centric view of ALS/FTD. While TDP-43 pathology is ubiquitous, its insolubility and associated splicing defects were found to be exclusive to the "like-C9" group, suggesting it's part of a broader RBP dysregulation rather than the sole initiating factor.
- Protein Aggregation Precedes or Coincides with Splicing Defects: The data strongly suggests that the insolubility and aggregation of RBPs (like hnRNP H and TDP-43) are upstream or concurrent with widespread splicing defects, rather than being solely downstream consequences of cell death.
- FTD as a More Advanced Stage: The "like-C9" phenotype, characterized by higher RBP insolubility and more global splicing changes, was significantly associated with a higher likelihood of FTD diagnosis. This supports a model where FTD represents a more advanced stage of this RBP proteinopathy spectrum.
- Multi-RBP Proteinopathy: The findings advocate for viewing ALS/FTD as a "multiRBP proteinopathy," where the interplay and aggregation of multiple RNA-binding proteins contribute to the disease, rather than a disease caused by a single protein's dysfunction.
Key Results
- Splicing Signature: Half of the 50 sporadic ALS/FTD patients analyzed showed aberrant splicing of hnRNP H targets, classifying them as "like-C9."
- Protein Insolubility: "Like-C9" patients had significantly higher levels of insoluble hnRNP H (1.78 times more than "like-control" patients). This insolubility strongly correlated with the magnitude of splicing dysregulation.
- TDP-43 and FUS Insolubility: Notably, TDP-43, FUS, and hnRNP A1 also showed increased insolubility in "like-C9" patients, correlating with splicing severity.
- FTD Predisposition: "Like-C9" patients were 3.8 times more likely to have FTD symptoms compared to "like-control" patients.
- RNA-seq Confirmation: Global RNA-seq analysis confirmed widespread splicing defects in ALS/FTD patients, with patterns correlating with hnRNP H insolubility.
Limitations and Future Work
- Sporadic Cases Heterogeneity: The study acknowledges that approximately half of sporadic ALS/FTD brains did not display significant splicing defects or insoluble protein. The authors propose that these cases might be driven by distinct mechanisms or represent earlier stages of the disease where changes are not yet detectable in bulk tissue.
- Cell-Type Specificity: It's suggested that splicing and solubility changes might be confined to specific vulnerable cell types and diluted in bulk tissue analysis. Future work could focus on single-cell or cell-type-specific analyses.
- Causality: While the study strongly suggests a common mechanism, definitively proving causality between RBP aggregation, splicing defects, and disease progression requires further investigation.
- Environmental Factors: The authors mention that some sporadic cases might be driven by environmental factors, which were not directly investigated in this study.
- Model Refinement: The authors propose a model where RBP insolubility is upstream of splicing defects, but also consider the possibility of reciprocal influence. Future work could further dissect these complex interactions.
Summary updated